Ocular Therapeutix announced positive Phase 3 results for AXPAXLI (OTX-TKI) in wet AMD, showing superiority over aflibercept at week 36 with high statistical significance5.
RGX-314 from Regenxbio is an exciting emerging gene therapy for wet AMD, potentially reducing frequent injections21.
Wet AMD market in the US was USD 2,599 million in 2023, expected to grow by 2036; EYLEA held the highest share at USD 4,276 million in 7MM1.
KOLs from Cleveland Clinic and Johns Hopkins provided insights on treatment landscape, patient switching, and accessibility challenges1.
EMA issued positive opinion for ONS-5010/LYTENAVA approval in EU for wet AMD in March 2024; BLA resubmission planned by end of 20247.
Emerging therapies like gene and stem cell options (e.g., RGX-314, Ixo-vec) aim to offer durable, one-time treatments1.
Sources:
1. https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
2. https://www.youtube.com/watch?v=vnsGtg-F0
5. https://www.eyeworld.org/2026/eyeworld-weekly-february-20-2026/
7. https://www.openpr.com/news/4440470/age-related-vision-dysfunction-market-high-growth